Prospective Analysis of Association Between Use of Statins or Other Lipid-Lowering Agents and Colorectal Cancer Risk

被引:46
作者
Simon, Michael S. [1 ,2 ]
Rosenberg, Carol A. [3 ]
Rodabough, Rebecca J. [4 ]
Greenland, Phillip [5 ]
Ockene, Ira [6 ]
Roy, Hemant K. [3 ]
Lane, Dorothy S. [7 ]
Cauley, Jane A. [8 ]
Khandekar, Janardan [3 ]
机构
[1] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Detroit, MI USA
[2] Wayne State Univ, Karmanos Canc Inst, Populat Studies & Prevent Program, Detroit, MI USA
[3] NorthShore Univ Hlth Syst, Evanston, IL USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Univ Massachusetts, Sch Med, Worcester, MA USA
[7] SUNY Stony Brook, Sch Med, Dept Prevent Med, Stony Brook, NY 11794 USA
[8] Univ Pittsburgh, Pittsburgh, PA USA
基金
美国国家卫生研究院;
关键词
Colorectal Cancer; Statins; Cancer Risk; Cohort Study; HUMAN COLON-CANCER; REDUCTASE INHIBITORS; PROSPECTIVE COHORT; UNITED-STATES; LOVASTATIN; CELLS; POPULATION; APOPTOSIS; ATORVASTATIN; PHARMACOLOGY;
D O I
10.1016/j.annepidem.2011.10.006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: To determine whether 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) are associated with a decreased risk of colorectal cancer. METHODS: The population included 159,219 postmenopausal women enrolled in the Women's Health Initiative in which 2000 pathologically confirmed cases of colorectal cancer were identified during an average of 10.7 (S.D. 2.9) years. Information on statins was collected at baseline and years 1, 3, 6, and 9. Self- and interviewer-administered questionnaires were used to collect information on other risk factors. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by the use of Cox proportional hazards regression to evaluate the relationship between statin use and risk. Statistical tests were two-sided. RESULTS: Statins were used by 12,030 (7.6%) women at baseline. The annualized colorectal cancer rate was 0.13% among users and 0.12% among nonusers. The multivariable adjusted HR for users versus nonusers was 0.99 (95% confidence interval [CI], 0.83-1.20, p = .95), and 0.79 (95% CI, 0.56-1.11) for users of >= 3 years. In the multivariable adjusted time-dependent model, the HR for lovastatin was 0.62 (95% CI, 0.39-0.99). There was no effect of tumor location, stage or grade. CONCLUSIONS: There was a reduction in colorectal cancer risk associated with lovastatin and a nonsignificant association with longer duration of use. Ann Epidemiol 2012;22:17-27. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 52 条
[1]   Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells [J].
Agarwal, B ;
Halmos, B ;
Feoktistov, AS ;
Protiva, P ;
Ramey, WG ;
Chen, M ;
Pothoulakis, C ;
Lamont, JT ;
Holt, PR .
CARCINOGENESIS, 2002, 23 (03) :521-528
[2]  
Agarwal B, 1999, CLIN CANCER RES, V5, P2223
[3]  
Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
[4]   Implementation of the Women's Health Initiative Study Design [J].
Anderson, GL ;
Manson, J ;
Wallace, R ;
Lund, B ;
Hall, D ;
Davis, S ;
Shumaker, S ;
Wang, CY ;
Stein, E ;
Prentice, RL .
ANNALS OF EPIDEMIOLOGY, 2003, 13 (09) :S5-S17
[5]  
[Anonymous], 2010, American Cancer Society: Cancer Facts and Figures
[6]   Effect of statin therapy on colorectal cancer [J].
Bardou, Marc ;
Barkun, Alan ;
Martel, Myriam .
GUT, 2010, 59 (11) :1572-1585
[7]   Low-fat dietary pattern and risk of colorectal cancer - The Women's Health Initiative randomized controlled dietary modification trial [J].
Beresford, SAA ;
Johnson, KC ;
Ritenbaugh, C ;
Lasser, NL ;
Snetselaar, LG ;
Black, HR ;
Anderson, GL ;
Assaf, AR ;
Bassford, T ;
Bowen, D ;
Brunner, RL ;
Brzyski, RG ;
Caan, B ;
Chlebowski, RT ;
Gass, M ;
Harrigan, RC ;
Hays, J ;
Heber, D ;
Heiss, G ;
Hendrix, SL ;
Howard, BV ;
Hsia, J ;
Hubbell, FA ;
Jackson, RD ;
Kotchen, JM ;
Kuller, LH ;
LaCroix, AZ ;
Lane, DS ;
Langer, RD ;
Lewis, CE ;
Manson, JE ;
Margolis, KL ;
Mossavar-Rahmani, Y ;
Ockene, JK ;
Parker, LM ;
Perri, MG ;
Phillips, L ;
Prentice, RL ;
Robbins, J ;
Rossouw, JE ;
Sarto, GE ;
Stefanick, ML ;
Van Horn, L ;
Vitolins, MZ ;
Wactawski-Wende, J ;
Wallace, RB ;
Whitlock, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (06) :643-654
[8]   Preclinical and clinical pharmacology of cerivastatin [J].
Bischoff, H ;
Heller, AH .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (4B) :18J-25J
[9]   3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study [J].
Blais, L ;
Desgagné, A ;
LeLorier, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2363-2368
[10]   Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients [J].
Bonovas, Stefanos ;
Filioussi, Kalitsa ;
Flordellis, Christodoulos S. ;
Sitaras, Nikolaos M. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) :3462-3468